OVERVIEW

2020-2021 Psychiatric Pharmacotherapy Review Course-Neurodevelopmental, Disruptive, Impulse-Control and Conduct Disorders is organized by College of Psychiatric and Neurologic Pharmacists (CPNP).

Activity Dates: 01/03/2020 - 12/31/2021

Target Audience:
If you are a pharmacist, nurse practitioner or other healthcare professional involved in the comprehensive medication management of psychiatric and/or neurological patients, we invite you to participate in this online course.

ACPE Contact Hours: 1.0

Session Summary:
This self-study course is designed to assist the learner in developing and maintaining contemporary knowledge and skills in the pharmacotherapy management of pediatric related diseases. Content includes a comprehensive outline focused on etiology, risk factors, pathophysiology and treatment of pediatric related diseases. Specific focus is placed on identifying common signs and symptoms based on DSM-5 criteria, resolving drug therapy problems and developing an appropriate monitoring plan.

Learning Objectives:
• Describe the signs and symptoms, diagnostic criteria, and pathophysiology for neurodevelopmental, disruptive, impulse-control, conduct and genetic disorders.
• Explain the use of common rating scales for research, diagnosis, and management of neurodevelopmental, disruptive, impulse-control, and conduct disorders.
• Discuss the efficacy of pharmacologic and nonpharmacologic treatment options (including natural products, if applicable) in the acute and long-term management of neurodevelopmental, disruptive, impulse-control, and conduct disorders.
• Outline the mechanisms of action, pharmacokinetic, pharmacodynamic, and pharmacogenetic properties (if applicable), adverse events, significant drug interactions, and warnings/precautions (including medical comorbidities, black box warnings, and REMS programs) for drugs used in neurodevelopmental, disruptive, impulse-control, and conduct disorders.
• Describe treatment guidelines and landmark clinical trials, including study design, strengths and weaknesses, and implications for practice for neurodevelopmental, disruptive, impulse-control, and conduct disorders.
• Select an evidence-based drug therapy regimen (drug, dose, schedule, and duration of therapy) for stabilizing symptoms and preventing relapse given the clinical presentation of a specific patient.
• Outline a plan for monitoring and managing the safety and efficacy of drug therapy.
• Describe the management of neurodevelopmental, disruptive, impulse-control, and conduct disorders in special populations (e.g., pregnancy/lactation, children, and elderly).
• Recognize the behavioral phenotypes, major medical complications, risk factors, pathogenesis, clinical course, and drug therapy treatment options for patients with the following syndromes:
? Down Syndrome
? Prader-Willi Syndrome
? Fragile X Syndrome
? Klinefelter’s Syndrome
? Rett’s Syndrome
• Identify essential information to discuss during patient education about drug therapy and organizations that advocate and provide resources for individuals with neurodevelopmental, disruptive, impulse-control, and conduct disorders.